Form 4: Nuvation Bio Director Acquires Stock Options

Nuvation Bio Inc. reports that Director Robert B. Bazemore acquired stock options for 123,397 shares of Class A Common Stock.

Summary

• Robert B. Bazemore, a Director at Nuvation Bio Inc., acquired stock options on May 21, 2026.
• The options grant the right to buy 123,397 shares of Class A Common Stock at an exercise price of $4.79 per share.
• These options are set to expire on May 20, 2036.
• Vesting is scheduled to occur on the earlier of the one-year anniversary of the grant date (May 21, 2026) or the next shareholder annual meeting, contingent upon continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard grant of stock options to a director, which is a common incentive mechanism.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The grant of options at a specific price point may indicate a favorable valuation at the time of the grant.

Risks

• The value of the stock options is directly tied to the future performance and stock price of Nuvation Bio Inc.
• Vesting is contingent on the Reporting Person's continuous service, meaning departure from the company before vesting would result in forfeiture of unvested options.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the market price of its Class A Common Stock relative to the $4.79 exercise price.

Management Comments

• 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Industry Context

StockSavvy.ai notes that insider grants of stock options are common in the biotechnology sector as a means to incentivize and retain key personnel, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It can also be seen as a positive signal of management confidence.
• Employees: The vesting schedule tied to continuous service reinforces employee retention efforts.
• Management: Directors are incentivized to drive company performance to increase the value of their options.

Next Steps

• Continuous service by Robert B. Bazemore through the vesting dates.
• Monitoring of Nuvation Bio Inc.'s stock performance relative to the option exercise price.

Key Dates

Keywords

stock options, insider trading, Nuvation Bio, NUVB, Director, beneficial ownership, Class A Common Stock, SEC Form 4